Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

StockNews.com downgraded shares of Novo Nordisk A/S (NYSE:NVO – Free Report) from a strong-buy rating to a buy rating in a ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...

According to 26 different analyst ratings, Novo (NYSE:NVO) has the highest target price of $168.39 which means it could more than double from the current levels if the optimistic scenario unfolds. A ...

Novo Nordisk may be reorganizing its early-stage R&D capabilities, but the Danish pharma’s chief scientific officer has insisted that the changes aren’t primarily about laying off staff. | Novo ...

Novo Nordisk released the results from its late-stage trial of CagriSema on Monday. It showed that patients on the highest ...

A class action lawsuit was filed against Novo Nordisk A/S (NVO) by Levi & Korsinsky on January 24, 2025. The plaintiffs ...

The Association of the British Pharmaceutical Industry (ABPI) reinstated Novo Nordisk’s membership in the group. 1 The ...

As China embarks on its three-year "weight management" campaign, Novo Nordisk has stepped forward with its powerful tools to ...

Novo Nordisk stock tumbled Monday morning after disappointing trial results for its CagriSema weight-loss drug. Shares in ...

The setback comes at a crucial time for Novo Nordisk, which had positioned CagriSema as its next-generation weight-loss ...

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, beating rival Novo Nordisk ...